期刊
INTERNATIONAL JOURNAL OF CANCER
卷 132, 期 10, 页码 2339-2348出版社
WILEY-BLACKWELL
DOI: 10.1002/ijc.27919
关键词
podoplanin; glioblastoma multiforme; medulloblastoma; recombinant immunotoxin; single-chain disulfide Fv
类别
资金
- National Cancer Institute [NINDS 5P50 NS20023-29, 5R37 CA011898-42]
- Southeastern Brain Tumor Foundation
- Silvian Foundation
- Intramural Research Program of the NIH
- National Cancer Institute
- Center for Cancer Research
- Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research
Our study demonstrates the glioma tumor antigen podoplanin to be present at very high levels (>90%) in both glioblastoma (D2159MG, D08-0308MG and D08-0493MG) and medulloblastoma (D283MED, D425MED and DAOY) xenografts and cell line. We constructed a novel recombinant single-chain antibody variable region fragment (scFv), NZ-1, specific for podoplanin from the NZ-1 hybridoma. NZ-1-scFv was then fused to Pseudomonas exotoxin A, carrying a C-terminal KDEL peptide (NZ-1-PE38KDEL). The immunotoxin (IT) was further stabilized by a disulfide (ds) bond between the heavy-chain and light-chain variable regions as the construct NZ-1-(scdsFv)-PE38KDEL. NZ-1-(scdsFv)-PE38KDEL exhibited significant reactivity to glioblastoma and medulloblastoma cells. The affinity of NZ-1-(scdsFv), NZ-1-(scdsFv)-PE38KDEL and NZ-1 antibody for podoplanin peptide was 2.1 x 108 M, 8.0 x 108 M and 3.9 x 1010 M, respectively. In a protein stability assay, NZ-1-(scdsFv)-PE38KDEL retained 3398% of its activity, whereas that of NZ-1-PE38KDEL declined to 13% of its initial levels after incubation at 37 degrees C for 3 days. In vitro cytotoxicity of the NZ-1-(scdsFv)-PE38KDEL was measured in cells isolated from glioblastoma xenografts, D2159MG, D08-0308MG and D08-0493MG, and in the medulloblastoma D283MED, D425MED and DOAY xenografts and cell line. The NZ-1-(scdsFv)-PE38KDEL IT was highly cytotoxic, with an 50% inhibitory concentration in the range of 1.629 ng/ml. Significantly, NZ-1-(scdsFv)-PE38KDEL demonstrated tumor growth delay, averaging 24 days (p < 0.001) and 21 days (p < 0.001) in D2159MG and D283MED in vivo tumor models, respectively. Crucially, in the D425MED intracranial tumor model, NZ-1-(scdsFv)-PE38KDEL caused a 41% increase in survival (p 0.001). In preclinical studies, NZ-1-(scdsFv)-PE38KDEL exhibited significant potential as a targeting agent for malignant brain tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据